* confirmed cases, suspected cases or asymptomatic infections of sar-cov-2 infection (check "china disease prevention and control information system"). * has a history of sars, mers infection (self-report, on-site inquiry). * \>14-year-old subjects axillary temperature ≥37.3℃, ≤14-year-old subjects axillary temperature ≥37.5℃. * previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. * with severe liver diseases, severe kidney diseases, uncontrollable hypertension (systolic blood pressure ≥160 mmhg, diastolic blood pressure ≥100 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. * has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases. * has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. * with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease). * received immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). * received live attenuated vaccinewithin 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. * received blood products within 3 months before enrolment. * received other research drugs within 6 months before enrolment. * other circumstances judged by investigators are not suitable for this clinical trial.

* confirmed cases, suspected cases or asymptomatic infections of sar-cov-2 infection (check "china disease prevention and control information system"). * has a history of sars, mers infection (self-report, on-site inquiry). * \>14-year-old subjects axillary temperature ≥37.3℃, ≤14-year-old subjects axillary temperature ≥37.5℃. * previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. * with severe liver diseases, severe kidney diseases, uncontrollable hypertension (systolic blood pressure ≥160 mmhg, diastolic blood pressure ≥100 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. * has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases. * has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. * with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. * has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease). * received immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). * received live attenuated vaccinewithin 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. * received blood products within 3 months before enrolment. * received other research drugs within 6 months before enrolment. * other circumstances judged by investigators are not suitable for this clinical trial.

- confirmed cases, suspected cases or asymptomatic infections of sar-cov-2 infection (check "china disease prevention and control information system"). - has a history of sars, mers infection (self-report, on-site inquiry). - >14-year-old subjects axillary temperature ≥37.3℃, ≤14-year-old subjects axillary temperature ≥37.5℃. - previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. - with severe liver diseases, severe kidney diseases, uncontrollable hypertension (systolic blood pressure ≥160 mmhg, diastolic blood pressure ≥100 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases. - has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. - with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease). - received immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). - received live attenuated vaccinewithin 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. - received blood products within 3 months before enrolment. - received other research drugs within 6 months before enrolment. - other circumstances judged by investigators are not suitable for this clinical trial.

- confirmed cases, suspected cases or asymptomatic infections of sar-cov-2 infection (check "china disease prevention and control information system"). - has a history of sars, mers infection (self-report, on-site inquiry). - >14-year-old subjects axillary temperature ≥37.3℃, ≤14-year-old subjects axillary temperature ≥37.5℃. - previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. - with severe liver diseases, severe kidney diseases, uncontrollable hypertension (systolic blood pressure ≥160 mmhg, diastolic blood pressure ≥100 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases. - has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. - with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease). - received immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). - received live attenuated vaccinewithin 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. - received blood products within 3 months before enrolment. - received other research drugs within 6 months before enrolment. - other circumstances judged by investigators are not suitable for this clinical trial.

- confirmed cases, suspected cases or asymptomatic infections of sar-cov-2 infection (check "china disease prevention and control information system"). - have a history of sars, mers infection (self-report, on-site inquiry). - >14-year-old subjects axillary temperature ≥37.3℃, ≤14-year-old subjects axillary temperature ≥37.5℃. - previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. - with severe liver diseases, severe kidney diseases , uncontrollable hypertension (systolic blood pressure ≥160 mmhg, diastolic blood pressure ≥100 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases. - has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. - with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease). - received immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). - received live attenuated vaccinewithin 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. - received blood products within 3 months before enrolment. - received other research drugs within 6 months before enrolment. - other circumstances judged by investigators that are not suitable for this clinical trial.

- confirmed cases, suspected cases or asymptomatic infections of sar-cov-2 infection (check "china disease prevention and control information system"). - have a history of sars, mers infection (self-report, on-site inquiry). - >14-year-old subjects axillary temperature ≥37.3℃, ≤14-year-old subjects axillary temperature ≥37.5℃. - previous severe allergic reactions to vaccination (such as acute allergic reactions, urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known ingredients of inactivated sars-cov-2 vaccine have occurred. - with severe liver diseases, severe kidney diseases , uncontrollable hypertension (systolic blood pressure ≥160 mmhg, diastolic blood pressure ≥100 mmhg), diabetic complications, malignant tumors, various acute diseases, or acute attack period of chronic diseases. - has been diagnosed with congenital or acquired immune deficiency, hiv infection, lymphoma, leukemia or other autoimmune diseases. - has a history of convulsion, epilepsy, encephalopathy or mental illness or family history. - with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc. - has a history of coagulation dysfunction (e.g. coagulation factor deficiency, coagulation disease). - received immunotherapy or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). - received live attenuated vaccinewithin 1 month before this vaccination, other vaccines are inoculated within 14 days before this vaccination. - received blood products within 3 months before enrolment. - received other research drugs within 6 months before enrolment. - other circumstances judged by investigators that are not suitable for this clinical trial.